Claudia Coelho, Laurence J Dobbie, James Crane, Abdel Douiri, Annastazia E Learoyd, Olanike Okolo, Spyros Panagiotopoulos, Dimitri J Pournaras, Sasindran Ramar, Francesco Rubino, Rishi Singhal, Carel W le Roux, Shahrad Taheri, Barbara McGowan
INTRODUCTION: Obesity drives type 2 diabetes (T2DM) development. Laparoscopic adjustable gastric banding (LAGB) has lower weight reduction than other bariatric procedures. Liraglutide, a GLP-1 receptor agonist, improves weight and glycaemic control in patients with T2DM. This study aimed to determine the efficacy and safety of liraglutide 1.8 mg in participants undergoing LAGB. METHODS: GLIDE, a pilot randomised, double-blind, placebo-controlled trial, evaluated LAGB with either liraglutide 1...
September 11, 2023: International Journal of Obesity